Clinical trial
PTC124 for Cystic Fibrosis
NCT00234663 · PTC Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00234663 |
|---|---|
| Title | PTC124 for Cystic Fibrosis |
| Official title | A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis |
| Lead sponsor | PTC Therapeutics, Industry |
| Collaborators | Cystic Fibrosis Foundation FDA Office of Orphan Products Development U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | PTC124 |
| Enrollment | 24 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Oct 7, 2005 |
| Last update posted | Jan 13, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: